medigraphic.com
SPANISH

Annals of Hepatology

Órgano Oficial de la Asociación Mexicana de Hepatología
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2016, Number 6

<< Back Next >>

Ann Hepatol 2016; 15 (6)

The effect of ursodeoxycholic acid in cystic cholangiopathies

Lammert F, Méndez-Sánchez N
Full text How to cite this article

Language: English
References: 9
Page: 949-950
PDF size: 106.95 Kb.


Key words:

No keywords

Text Extraction

Comment:

We have read with great interest the publication from Hedwig D’Agnolo, et al. on the effect of ursodeoxycholic acid (UDCA) in advanced polycystic liver disease due to autosomal-dominant polycystic kidney and/or liver diseases (ADPKD/ADPLD). The Dutch group of investigators reported interesting results on UDCA administration for 24 weeks. They reported a reduction of liver cyst volume growth but did not observe a reduction of total liver volume.


REFERENCES

  1. D’Agnolo HM, Kievit W, Takkenberg RB, et al. Ursodeoxycholic acid in advanced polycystic liver disease: A phase 2 multicenter randomized controlled trial. J Hepatol 2016; 65: 601-7.

  2. Lazaridis KN, LaRusso NF. The Cholangiopathies. Mayo Clin Proc 2015; 90: 791-800.

  3. Munoz-Garrido P, Marin JJ, Perugorria MJ, et al. Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease. J Hepatol 2015; 63: 952-61.

  4. Iijima T, Hoshino J, Suwabe T, et al. Ursodeoxycholic Acid for Treatment of Enlarged Polycystic Liver. Ther Apher Dial 2016; 20: 73-8.

  5. van der Feen C, van der Doef HP, van der Ent CK, Houwen RH. Ursodeoxycholic acid treatment is associated with improvement of liver stiffness in cystic fibrosis patients. J Cyst Fibros 2016: S1569-199330566-5.

  6. Combes B1, Carithers RL Jr, Maddrey WC, et al. Biliary bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 1999; 29: 1649-54.

  7. Fickert P, Wagner M, Marschall HU, et al. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2006; 130: 465-81.

  8. Hayashi H1, Takada T, Suzuki H, Onuki R, Hofmann AF, Sugiyama Y. Transport by vesicles of glycine- and taurine-conjugated bile salts and taurolithocholate 3-sulfate: a comparison of human BSEP with rat Bsep. Biochim Biophys Acta 2005; 1738: 54-62.

  9. Úriz M, Sáez E, Prieto J, Medina JF, Banales JM. Ursodeoxycholic acid is conjugated with taurine to promote secretinstimulated biliary hydrocholeresis in the normal rat. PLoS One 2011; 6: e28717.




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Ann Hepatol. 2016;15